相关实验视频

Updated: Jun 24, 2025

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

黑德拉根醇通过调节Th17细胞分化来改善多发性硬化症

Dongsheng Guan¹, Yingxia Li², Xu Zhao³

¹Department of Neurology, the Second Clinical Medical College, Henan University of Traditional Chinese Medicine, Zhengzhou, China.

|June 5, 2024

概括

甲醇 (Hed) 通过减少有害的Th17细胞,减轻小鼠多发性硬化症 (MS) 的症状. 这种化合物向RORγt促进体,为MS提供了潜在的新治疗策略.

科学领域:

神经免疫学神经免疫学
自免疫性疾病自免疫性疾病
药理学药理学是指药理学的学科.

背景情况:

多发性硬化症 (MS) 是一种衰弱的自身免疫性疾病,其特征是炎症和神经退行.
辅助性T细胞17 (Th17) 通过产生促炎性细胞因子IL-17. 在MS的发病过程中起着至关重要的作用.
原醇 (Hed) 是一种天然化合物,在调节IL-17方面表现出潜力,但其在MS中的特定作用需要阐明.

研究的目的:

为了研究Hederagenol (Hed) 在实验性自身免疫脑膜炎 (EAE) 的治疗潜力,MS的小鼠模型.
为了确定Hed是否通过调节Th17细胞分化来改善MS.
确定多发性硬化症治疗的潜在新治疗点.

主要方法:

用Hederagenol (Hed) 诱导和治疗EAE小鼠模型.
评估临床症状,脊髓炎,脱髓和神经损伤.
流细胞计和定量PCR/Western blot用于分析T细胞子集和RORγt表达.
染色体免疫沉以评估RORγt促进体活性.

主要成果:

在EAE小鼠中,治疗显著降低了临床症状,脊髓炎症,脱髓和神经损伤.
它的使用降低了脊髓和脏中的Th17细胞数量.
它降低了RORγt水平和RORγt促进器活性,表明Th17差异化的调节.
过度表达RORγt抵消了Hed对Th17分化抑制作用.

结论:

甲醇 (Hed) 有效地改善了EAE症状和神经病理学.
它通过通过RORγt通路调节抑制Th17细胞分化来发挥其治疗作用.
代表了一种有前途的MS治疗药物,针对Th17介导的神经炎症.

关键词:

欧洲电子商务管理局 (EEAE)这就是Hederagenol.Th17差异化差异化方法多发性硬化症多发性硬化症

更多相关视频

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...